Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    Glembatumumab Vedotin | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Condition: Squamous Cell Carcinoma of the Lung
Interventions: Drug: Phase I: Glembatumumab Vedotin;   Drug: Phase II: Glembatumumab Vedotin
2 Recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Recruiting A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Condition: Melanoma
Interventions: Drug: glembatumumab vedotin;   Drug: glembatumumab vedotin and varlilumab;   Drug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
4 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions: Drug: CDX-011;   Drug: Capecitabine
5 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin

Study has passed its completion date and status has not been verified in more than two years.